Barinthus Biotherapeutics plc (2AB.F)

2,0200 0,0000 (0,00%) Börsenschluss: 08:00AM CEST

Barinthus Biotherapeutics plc

Zeus Building
Unit 6-10 Rutherford Avenue Harwell
Didcot OX11 0DF
United Kingdom
44 1865 818 808
https://www.barinthusbio.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 130

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. William J. Enright MBA	CEO & Director	901,81k	N/A	1962
Dr. Nadege Pelletier Ph.D.	Chief Scientific Officer	552,08k	N/A	1979
Mr. Graham Griffiths	Chief Business Officer	485,8k	N/A	1980
Ms. Sarah Gilbert	Co-Founder	45,57k	N/A	N/A
Mr. Adrian Hill Ph.D.	Co-Founder & Scientific Advisor	57,31k	N/A	N/A
Ms. Gemma Brown	CFO & Company Secretary	N/A	N/A	1991
Ms. Elizabeth Eagling-Vose M.B.A.	Head of Clinical Operations	N/A	N/A	N/A
Bernie McDonald	Head of IP	N/A	N/A	N/A
Geoffrey Lynn	Senior Vice President of Synthetic Immunotherapies	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

Corporate Governance

Barinthus Biotherapeutics plcs ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.